Acarix AB ("Acarix" or the "Company") has completed the new share issue of a maximum of
86,156,738 shares with preferential rights for the Company's existing shareholders, which was
resolved by the extra general meeting on 11 August 2020 (the "Rights Issue"). Acarix today
announces the final outcome of the Rights Issue, which shows, in line with what was
communicated 9 September 2020, that the Rights Issue has been oversubscribed.
Acarix was establish in 2009 and is listed on Nasdaq First North Growth Market. Acarix's CADScor@System uses an advanced sensor placed on the skin above the heart to listen to the sounds of cardiac contraction movement and turbulent flow. It has been designed to be an all-in-on system in the sense that the heart signal will be recorded, processed, and displayed as a patient specific score, the CAD-score, on the device screen.